Cameron Arkin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cameron Arkin has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
- Zachary J. Kastenberg
Division of Pediatric Surgery, Department of Surgery, Primary Children's Hospital University of Utah School of Medicine Salt Lake City Utah USA
4 shared publications - Jennifer H. Aldrink
Division of Pediatric Surgery, Department of Surgery, Nationwide Children's Hospital The Ohio State University College of Medicine Columbus Ohio USA
3 shared publications - Marcus M. Malek
Division of Pediatric General and Thoracic Surgery, Department of Surgery, UPMC Children's Hospital of Pittsburgh University of Pittsburgh School of Medicine Pittsburgh Pennsylvania USA
3 shared publications - Aaron Barkhordar
Division of Pediatric Surgery Cedars‐Sinai Medical Center Los Angeles California USA
2 shared publications - Brian T. Craig
Division of Pediatric Surgery, Department of Surgery, Children's Wisconsin, Medical College of Wisconsin Milwaukee Wisconsin USA
2 shared publications - Catherine B. Beckhorn
Division of Pediatric Surgery, Department of Surgery, Duke Children's Hospital and Health Center Duke University Medical Center Durham North Carolina USA
2 shared publications
Latest Publications
- 20 November 2026
- Published by Wiley in Pediatric Blood & Cancer
Indocyanine Green Assists in Identification of Solid Tumor Pulmonary Metastases
Background: The presence of pulmonary metastases reduces overall survival in patients with certain solid tumors; therefore, surgical clearance is crucial to cure for some types. This multi‐institutional prospective study sought to determine the utility and diagnostic accuracy of indocyanine green (ICG) for delineating pulmonary metastases in diverse pediatric, adolescent, and young adult solid cancers. Procedure: Thirteen member institutions of the Pediatric Surgical Oncology Research Collaborative administered preoperative ICG to patients undergoing pulmonary metastasectomy for primary or recurrent solid tumor malignancy (2019–2023). Surgeons reported their perspective on ICG utility for pulmonary metastasectomy following each operation. The diagnostic accuracy of ICG fluorescence to identify a pathologically confirmed tumor‐containing specimen was determined. Results: Of 829 specimens resected during 134 pulmonary metastasectomies (30.6% hepatic, 47.0% osteosarcoma, 17.2% non‐osteosarcoma‐type sarcomas [“other sarcomas”], 5.2% other non‐hepatic and non‐sarcoma tumor types [“other tumor types”]). Surgeons reported ICG as helpful in 77.6% of procedures. In 11.9% of cases, ICG identified viable metastases not visualized on preoperative imaging. Adjusted diagnostic accuracy and sensitivity (95% confidence interval [CI]) for metastases from all tumor types was 80.7% (77.9%–83.3%) and 82.5% (78.9%–85.8%), respectively. By primary tumor histology, adjusted accuracy and sensitivity (95% CI) were 83.2% (74.4%–89.9%), 46.7% (28.3%–65.7%) for metastases from other sarcomas, 80.6% (75.3%–85.2%), 95.6% (91.8%–98.0%) for hepatic tumors, 80.6% (76.6%–84.2%), 77.1% (71.4%–82.2%) for osteosarcoma, and 72.7% (49.8%–89.3%), 60.0% (26.2%–87.8%) for other tumor types. Conclusions: During pulmonary metastasectomy, adjusted diagnostic accuracy of ICG was 80.7%, and, importantly, 11.9% of metastasectomies contained viable tumors identified by ICG but not by preoperative imaging.
- 20 November 2026
- Published by Wiley in Pediatric Blood & Cancer
Indocyanine Green Assists in Identification of Solid Tumor Pulmonary Metastases
Background: The presence of pulmonary metastases reduces overall survival in patients with certain solid tumors; therefore, surgical clearance is crucial to cure for some types. This multi‐institutional prospective study sought to determine the utility and diagnostic accuracy of indocyanine green (ICG) for delineating pulmonary metastases in diverse pediatric, adolescent, and young adult solid cancers. Procedure: Thirteen member institutions of the Pediatric Surgical Oncology Research Collaborative administered preoperative ICG to patients undergoing pulmonary metastasectomy for primary or recurrent solid tumor malignancy (2019–2023). Surgeons reported their perspective on ICG utility for pulmonary metastasectomy following each operation. The diagnostic accuracy of ICG fluorescence to identify a pathologically confirmed tumor‐containing specimen was determined. Results: Of 829 specimens resected during 134 pulmonary metastasectomies (30.6% hepatic, 47.0% osteosarcoma, 17.2% non‐osteosarcoma‐type sarcomas [“other sarcomas”], 5.2% other non‐hepatic and non‐sarcoma tumor types [“other tumor types”]). Surgeons reported ICG as helpful in 77.6% of procedures. In 11.9% of cases, ICG identified viable metastases not visualized on preoperative imaging. Adjusted diagnostic accuracy and sensitivity (95% confidence interval [CI]) for metastases from all tumor types was 80.7% (77.9%–83.3%) and 82.5% (78.9%–85.8%), respectively. By primary tumor histology, adjusted accuracy and sensitivity (95% CI) were 83.2% (74.4%–89.9%), 46.7% (28.3%–65.7%) for metastases from other sarcomas, 80.6% (75.3%–85.2%), 95.6% (91.8%–98.0%) for hepatic tumors, 80.6% (76.6%–84.2%), 77.1% (71.4%–82.2%) for osteosarcoma, and 72.7% (49.8%–89.3%), 60.0% (26.2%–87.8%) for other tumor types. Conclusions: During pulmonary metastasectomy, adjusted diagnostic accuracy of ICG was 80.7%, and, importantly, 11.9% of metastasectomies contained viable tumors identified by ICG but not by preoperative imaging.
- Open Access
- 5 June 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (6) , e70367
Early Living Donor Liver Transplant Is Associated With Improved Graft‐ and Patient‐Survival Outcomes in Children With Biliary Atresia
Introduction: Biliary atresia ( BA ) is the most common indication for pediatric liver transplantation. Pediatric end‐stage liver disease ( PELD ) scores primarily determine deceased donor liver transplant ( DDLT ) waitlist priority. Due to persistent donor supply–demand mismatch, children typically have advanced disease and high PELD scores at the time of DDLT . Proactive living donor liver transplant ( LDLT ) may facilitate transplantation before critical illness. We hypothesized that early, low PELD , LDLT is associated with improved graft and patient survival in children with BA. Methods: We retrospectively reviewed children undergoing liver transplantation for BA in the SRTR database, comparing DDLT to LDLT , stratified by PELD . Early transplant was defined as transplant with a PELD ≤ 12. Four groups were analyzed: low PELD LDLT , low PELD DDLT , high PELD LDLT , and high PELD DDLT . Kaplan–Meier and Cox‐proportional hazards analyses evaluated patient‐ and graft‐survival. Results: 4733 children meeting inclusion criteria were included ( n = 249 Low PELD LDLT, n = 1152 Low PELD DDLT, n = 708 High PELD LDLT, n = 2624 High PELD DDLT). Prior to transplant, Low PELD LDLT recipients had lower INR and bilirubin levels, and required less life support ( p < 0.01). Kaplan–Meier analyses showed the highest 5‐year graft and patient survival in the Low PELD LDLT ( p < 0.01). Cox modeling revealed an independent association between low PELD LDLT and decreased graft loss (adjusted HR 0.45, p < 0.01) and mortality (adjusted HR 0.43, p = 0.03). Conclusions: A proactive approach to LDLT in children with BA is associated with improved long‐term graft and patient survival. Low PELD LDLT should be considered to increase early transplant access for children with BA .
- 5 June 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (6) , e70367
Open AccessEarly Living Donor Liver Transplant Is Associated With Improved Graft‐ and Patient‐Survival Outcomes in Children With Biliary Atresia
Introduction: Biliary atresia ( BA ) is the most common indication for pediatric liver transplantation. Pediatric end‐stage liver disease ( PELD ) scores primarily determine deceased donor liver transplant ( DDLT ) waitlist priority. Due to persistent donor supply–demand mismatch, children typically have advanced disease and high PELD scores at the time of DDLT . Proactive living donor liver transplant ( LDLT ) may facilitate transplantation before critical illness. We hypothesized that early, low PELD , LDLT is associated with improved graft and patient survival in children with BA. Methods: We retrospectively reviewed children undergoing liver transplantation for BA in the SRTR database, comparing DDLT to LDLT , stratified by PELD . Early transplant was defined as transplant with a PELD ≤ 12. Four groups were analyzed: low PELD LDLT , low PELD DDLT , high PELD LDLT , and high PELD DDLT . Kaplan–Meier and Cox‐proportional hazards analyses evaluated patient‐ and graft‐survival. Results: 4733 children meeting inclusion criteria were included ( n = 249 Low PELD LDLT, n = 1152 Low PELD DDLT, n = 708 High PELD LDLT, n = 2624 High PELD DDLT). Prior to transplant, Low PELD LDLT recipients had lower INR and bilirubin levels, and required less life support ( p < 0.01). Kaplan–Meier analyses showed the highest 5‐year graft and patient survival in the Low PELD LDLT ( p < 0.01). Cox modeling revealed an independent association between low PELD LDLT and decreased graft loss (adjusted HR 0.45, p < 0.01) and mortality (adjusted HR 0.43, p = 0.03). Conclusions: A proactive approach to LDLT in children with BA is associated with improved long‐term graft and patient survival. Low PELD LDLT should be considered to increase early transplant access for children with BA .
- Open Access
Indocyanine green assists with sentinel lymph node mapping in pediatric and adolescent patients: A Pediatric Surgical Oncology Research Collaborative prospective observational study
Background: Sentinel lymph node (SLN) biopsy is a critical staging tool in skin and soft tissue cancers. Although technetium lymphoscintigraphy is the most common adjunct, indocyanine green (ICG) demonstrates a promising alternative in pediatric, adolescent, and young adult (AYA) skin and soft tissue cancers. Methods and Objectives: Evaluate the safety and efficacy of ICG in SLN biopsy (SLNB) in diverse pediatric and AYA solid cancers in a multi‐institutional environment. This is a prospective, observational study conducted at 13 member institutions in the Pediatric Surgical Oncology Research Collaborative between 2019 and 2023. Eligible patients underwent SLNB for primary or recurrent solid skin and soft tissue tumors. Peritumoral ICG was administered intraoperatively. Outcomes included SLN detection rates, histopathology of excised specimens, and surgeon‐reported assessment of utility. Safety was assessed through adverse event reporting. Results: Forty SLNB procedures yielded 84 specimens: 13 melanoma (32.5%), 12 squamous cell carcinoma (30%), 11 non‐rhabdomyosarcoma soft tissue sarcoma (27.5%), two rhabdomyosarcoma (5%), one Ewing sarcoma (2.5%), and one malignant peripheral nerve sheath tumor (2.5%). Histologic evaluation identified 81 lymph nodes, 75 benign (89.3%) and six malignant (7.1%); three specimens were adipose tissue (3.6%). Of 81 lymph nodes, 76% were ICG‐positive. ICG had a sensitivity of 79.5%, a specificity of 33%, and a positive predictive value of 96%. All malignant nodes were ICG‐avid. There were no adverse reactions to ICG at 30 days. Conclusions: ICG is a safe and effective adjunct for SLNB in pediatric and AYA soft tissue and skin malignancies.
Open AccessIndocyanine green assists with sentinel lymph node mapping in pediatric and adolescent patients: A Pediatric Surgical Oncology Research Collaborative prospective observational study
Background: Sentinel lymph node (SLN) biopsy is a critical staging tool in skin and soft tissue cancers. Although technetium lymphoscintigraphy is the most common adjunct, indocyanine green (ICG) demonstrates a promising alternative in pediatric, adolescent, and young adult (AYA) skin and soft tissue cancers. Methods and Objectives: Evaluate the safety and efficacy of ICG in SLN biopsy (SLNB) in diverse pediatric and AYA solid cancers in a multi‐institutional environment. This is a prospective, observational study conducted at 13 member institutions in the Pediatric Surgical Oncology Research Collaborative between 2019 and 2023. Eligible patients underwent SLNB for primary or recurrent solid skin and soft tissue tumors. Peritumoral ICG was administered intraoperatively. Outcomes included SLN detection rates, histopathology of excised specimens, and surgeon‐reported assessment of utility. Safety was assessed through adverse event reporting. Results: Forty SLNB procedures yielded 84 specimens: 13 melanoma (32.5%), 12 squamous cell carcinoma (30%), 11 non‐rhabdomyosarcoma soft tissue sarcoma (27.5%), two rhabdomyosarcoma (5%), one Ewing sarcoma (2.5%), and one malignant peripheral nerve sheath tumor (2.5%). Histologic evaluation identified 81 lymph nodes, 75 benign (89.3%) and six malignant (7.1%); three specimens were adipose tissue (3.6%). Of 81 lymph nodes, 76% were ICG‐positive. ICG had a sensitivity of 79.5%, a specificity of 33%, and a positive predictive value of 96%. All malignant nodes were ICG‐avid. There were no adverse reactions to ICG at 30 days. Conclusions: ICG is a safe and effective adjunct for SLNB in pediatric and AYA soft tissue and skin malignancies.
- Open Access
- 10 November 2024
- Published by Elsevier in Pediatric Hematology Oncology Journal
- Vol. 10 (1) , 20-23
Current management of pulmonary relapse in Ewing sarcoma: A report from the Pediatric Surgical Oncology Research Collaborative
- 10 November 2024
- Published by Elsevier in Pediatric Hematology Oncology Journal
- Vol. 10 (1) , 20-23
Open AccessCurrent management of pulmonary relapse in Ewing sarcoma: A report from the Pediatric Surgical Oncology Research Collaborative
- 22 August 2022
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 57 (12) , 1029-1030
Stapled neoappendicostomy: A novel technique
- 22 August 2022
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 57 (12) , 1029-1030
Stapled neoappendicostomy: A novel technique